BNBX
BNB Plus Corp.
NASDAQ · Healthcare · Biotechnology · US
$0.16
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.1M | 2.1M | 3.4M | 13.4M | 18.2M |
| Cost of Revenue | 1.2M | 1.3M | 2.4M | 7.8M | 13.1M |
| Gross Profit | 910.3K | 838.9K | 1.0M | 5.5M | 5.1M |
| Operating Expenses | |||||
| R&D Expense | 2.1M | 6.0M | 3.6M | 3.7M | 3.9M |
| SG&A Expense | 21.3M | 10.9M | 11.4M | 12.8M | 15.1M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.8M | — | — | — | — |
| Total Operating Expenses | 26.2M | 16.9M | 15.0M | 16.5M | 19.0M |
| Cost and Expenses | 27.4M | 18.2M | 17.5M | 24.3M | 32.1M |
| Operating Income (EBIT) | (25.3M) | (16.0M) | (14.0M) | (11.0M) | (14.0M) |
| Non-Operating | |||||
| Interest Income | 77.3K | 192.9K | 176.3K | 75.3K | 7.2K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 77.3K | 192.9K | 176.3K | 75.3K | 7.2K |
| Other Non-Op Income/Expense | (9.7M) | 406.0K | 6.9M | 930.4K | 5.7M |
| Non-Operating Income (excl Interest) | 9.7M | (406.0K) | (6.9M) | (930.4K) | (5.7M) |
| EBT (Pre-Tax Income) | (35.0M) | (15.6M) | (7.1M) | (10.0M) | (8.3M) |
| Income Tax Expense | (684.1K) | (684.1K) | — | — | — |
| Bottom Line | |||||
| Net Income | (34.5M) | (15.2M) | (7.0M) | (9.9M) | (8.3M) |
| Earnings from Cont. Ops | (34.3M) | (15.0M) | (7.1M) | (10.0M) | (8.3M) |
| Earnings from Discont. Ops | (325.8K) | (392.7K) | — | — | — |
| Bottom Line Net Income | (50.0M) | (69.5M) | (7.2M) | (9.9M) | (8.4M) |
| Per Share | |||||
| Basic EPS | ($39.93) | ($134.23) | ($68.25) | ($570.37) | ($9,741.86) |
| Diluted EPS | ($39.93) | ($134.23) | ($68.25) | ($570.37) | ($9,741.86) |
| Revenue Per Share | $0.22 | $4.13 | $32.45 | $766.79 | $21,126.37 |
| Shares | |||||
| Basic Shares Outstanding | 9.7M | 517671 | 105760 | 17433 | 860 |
| Diluted Shares Outstanding | 9.7M | 517671 | 105760 | 17433 | 860 |
| Profitability Metrics | |||||
| EBITDA | (34.7M) | (15.3M) | (6.4M) | (8.7M) | (7.0M) |
| D&A | 275.9K | 384.2K | 696.4K | 1.4M | 1.3M |
| EBIT | (35.0M) | (15.6M) | (7.1M) | (10.0M) | (8.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026